News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MannKind Corporation (MNKD) Reports 2012 First Quarter Financial Results


5/10/2012 10:44:40 AM

VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2012. For the first quarter of 2012, total operating expenses were $33.9 million, compared to $38.1 million for the first quarter of 2011, a decrease of $4.1 million. Research and development (R&D) expenses were $24.2 million for the first quarter of 2012 compared to $26.3 million for the same quarter in 2011, a decrease of $2.1 million. This 8% decrease was primarily due to the decrease in salary related costs as a result of the February 2011 reduction in force, partially offset by an increase in clinical trial related activities. General and administrative (G&A) expenses decreased by $2.0 million to $9.8 million for the first quarter of 2012 compared to $11.8 million in the first quarter of 2011. This 17% decrease in G&A expense was primarily due to the decrease in salary related costs as a result of the February 2011 reduction in force.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES